Skip to content

Clinical trials

Hyperlipoproteinemia Type II trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperlipoproteinemia Type II Country / region: United Kingdom Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20072
20081
20112
20121
20141
20152
20162
20172
20223
20232
20244
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Recruiting6
Unknown status3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals4
Verve Therapeutics, Inc.4
Amgen3
Kastle Therapeutics, LLC2
Alnylam Pharmaceuticals1
Cerenis Therapeutics, SA1
Genzyme, a Sanofi Company1
Imperial College London1
Merck Sharp & Dohme LLC1
NewAmsterdam Pharma1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperlipoproteinemia Type II23
Hypercholesterolemia13
Homozygous Familial Hypercholesterolemia7
Atherosclerosis5
Dyslipidemias5
Hyperlipidemias5
Cardiovascular Diseases4
Genetic Diseases, Inborn3
Hyperlipoproteinemias3
Lipid Metabolism Disorders3

Trials

Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.